Ascelia: Takeaways from Q1 ahead of top-line results by mid-2023 - Redeye

The main points is that Ascelia reminds investors that Last Patient Last Visit (LPLV) was completed in March and that Ascelia reminas on track to deliver headline results from the pivotal SPARKLE study by mid-2023. The operational loss is contained as a result of a reduced R&D costs. This is also why the cash position is also somewhat better than we expected.

Länk till analysen i sin helhet: https://www.redeye.se/research/905997/ascelia-takeaways-from-q1-ahead-of-top-line-results-by-mid-2023?utm_source=finwire&utm_medium=RSS